Solid Biosciences Inc. — FY2023 Form 10-K
Reporting period: Year ended December 31, 2023; filed March 13, 2024. This is an annual report, not a standalone fourth-quarter filing. Solid is a clinical-stage gene therapy company developing treatments for rare neuromuscular and cardiac diseases. It has not generated product sales.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Collaboration revenue | $0 | $8.1 million |
| Research and development expense | $76.6 million | $78.4 million |
| General and administrative expense | $27.8 million | $28.9 million |
| Operating loss | $104.3 million | $106.5 million |
| Net loss | $96.0 million | $86.0 million |
| Net loss per share, diluted | $4.83 | $10.10 |
| Cash used in operating activities | $94.2 million | $98.0 million |
At December 31, 2023, cash and cash equivalents were $74.0 million and available-for-sale securities were $49.6 million, totaling $123.6 million; restricted cash was an additional $1.8 million. Total assets were $164.9 million, total liabilities $38.5 million, and stockholders’ equity $126.5 million. The company reported no debt outstanding; liabilities included operating and finance lease obligations. No revenue or profit margin from product sales is available because the company has no approved commercial product.
Management says year-end liquidity plus approximately $104.0 million of net proceeds from a January 2024 private placement is expected to fund operations and capital needs into 2026. This estimate depends on assumptions and could prove inaccurate. The 2023 operating cash outflow was largely consistent with the net loss. Cash decreased by $81.4 million during 2023; investing activities provided $9.7 million and financing activities provided $3.1 million.
Material changes versus FY2022
- Net loss increased by $10.0 million, despite a $10.3 million reduction in total operating expenses. FY2022 included an $18.2 million gain on the AavantiBio acquisition; FY2023 did not.
- Collaboration revenue fell by $8.1 million to zero after the remaining revenue under the Ultragenyx research-services arrangement was recognized in 2022. No new research and development work under that arrangement was underway in 2023.
- R&D spending shifted toward SGT-003: spending rose to $20.9 million from $10.0 million, while SGT-001 spending fell to $3.4 million from $24.8 million. SGT-501 incurred $3.2 million in 2023.
- G&A expense declined modestly to $27.8 million, and restructuring expense was a $0.1 million credit versus $7.2 million of expense in 2022.
- Cash and cash equivalents plus available-for-sale securities declined from $213.7 million to $123.6 million. The January 2024 financing subsequently raised $104.0 million net, but issued 16.97 million shares and pre-funded warrants for 2.71 million shares.
Outlook, commentary, and key risks
- SGT-003 for Duchenne: FDA cleared the IND in November 2023. Solid planned to dose the first patient in its Phase 1/2 INSPIRE trial in Q2 2024, with an initial safety update anticipated in mid-2024 and initial data in the second half of 2024, subject to dosing. SGT-003 has FDA orphan drug and Fast Track designations.
- SGT-501 for CPVT: remains in preclinical development; Solid anticipated submitting an IND in early 2025. It has FDA and EMA orphan drug designations. Other cardiac and Friedreich’s ataxia programs are at earlier stages.
- Solid expects continued losses and substantial development spending and has never completed a clinical trial. It may need additional financing beyond the stated runway; financing could dilute shareholders or require less favorable strategic arrangements.
- Key risks include gene-therapy safety and efficacy uncertainty, potential clinical holds or serious adverse events, manufacturing scale-up and third-party supply dependence, trial enrollment and regulatory delays, competition, and the possibility that SGT-003 or other candidates fail to obtain approval.
- Other notable exposures include lease commitments, contingent license milestone and royalty obligations, and reliance on in-licensed intellectual property. No material legal proceedings were reported. The auditor identified external R&D costs and related accruals as a critical audit matter; the financial statement audit opinion was unqualified.
Important facts for investors to verify
- Whether INSPIRE began dosing on schedule and what the complete safety and clinical data show, including any changes to the company’s stated 2024 update timing.
- Whether manufacturing lots for clinical supply meet specifications and whether production capacity can support the SGT-003 trial and future development.
- Actual cash burn and remaining liquidity versus management’s “into 2026” estimate, including the effects of the January 2024 financing and resulting dilution.
- Progress and funding responsibilities under the Ultragenyx collaboration, and the development pace and costs of SGT-501 and the acquired AavantiBio programs.
- Potential gene-therapy safety findings, regulatory requirements, competition, and any changes in the scope or timing of clinical plans.